Skip to content
PubMed This is a summary of 13 peer-reviewed journal articles Updated
Hematology · Myeloid/Lymphoid Neoplasm With JAK2 Rearrangement

Building Your Care Team and Preparing for Consultation

At a Glance

An experienced rare blood cancer center can help confirm a myeloid/lymphoid neoplasm with JAK2 rearrangement, interpret genetic tests, discuss transplant, and coordinate care. Bring original bone marrow, genetic, imaging, and treatment records to the consultation.

Because a myeloid/lymphoid neoplasm (MLN) with a JAK2 rearrangement is so rare, your care benefits greatly from expert review. While many patients are managed successfully by a local oncologist, having your treatment plan guided by a “multidisciplinary” approach at an experienced center is highly recommended [1][2].

Your Essential Care Team

You should consider consulting with a large academic medical center or a “Center of Excellence” for rare blood cancers. Your core team may include:

  • Hematologist-Oncologist (Leukemia Specialist): This doctor leads your care and manages your daily treatments. They often co-manage your care with your local physician [3].
  • Hematopathologist: A specialist who looks at your blood and bone marrow under a microscope. Their expertise is critical for distinguishing this disease from “look-alikes” [4][5].
  • Transplant Physician: Because a stem cell transplant is a potentially curative option, consulting with a transplant specialist early in your journey is wise [2][6].
  • Cardio-Oncologist: If you have high levels of eosinophils (hypereosinophilia), you may need a cardiologist who understands how these cells can damage the heart. They use specialized imaging if indicated [7][8].
  • Molecular Geneticist: This specialist helps interpret the complex DNA and RNA tests [1][9].

Preparing for Your First Major Appointment

When you visit a specialist for a second opinion or to start treatment, you need the raw data from your diagnosis.

The Diagnostic “Package” to Bring:

  • Pathology Material: Request your original bone marrow biopsy “blocks” and “slides” from the hospital where the biopsy was performed [5].
  • Genetic Reports: This includes your karyotype, FISH reports, and any Next-Generation Sequencing (NGS) or RNA sequencing results [10][9].
  • Imaging and Scans: Any reports or discs containing CT scans or echocardiograms [11][7].
  • Clinical Timeline: A list of when symptoms started, blood counts, and medications [11].

Vetting a Specialty Center

When you meet your new team, ask about their experience with this specific genetic rearrangement. A center prepared for MLN-JAK2 should be able to explain how they integrate genetic data into their decisions [1][2].

Ask specifically about their access to validated fusion testing. Finding “cryptic” fusions often requires specific assays (like targeted RT-PCR, hybrid panels, or RNA sequencing) [9][12]. Ensuring the lab can accurately identify and track the JAK2 partner provides you with the most precise care [3][13].

Common questions in this guide

Why should I seek expert review for a JAK2-rearranged MLN?
This is a rare blood cancer, and diagnosis may require expert review of bone marrow findings and genetic tests. An experienced center can coordinate specialists, clarify the JAK2 fusion, and help plan treatment while continuing to work with your local hematologist.
Which specialists may be involved in my care?
A hematologist-oncologist usually leads care, with a hematopathologist reviewing blood and bone marrow findings. Depending on your situation, a transplant physician, molecular geneticist, or cardio-oncologist may also be involved, especially if you have high eosinophil levels or heart-related symptoms.
What records should I bring to a specialist consultation?
Bring the original bone marrow biopsy slides and blocks, genetic reports such as karyotype and FISH results, and any next-generation or RNA sequencing results. Also bring imaging reports or discs, blood-count and symptom timelines, and a current medication list.
How can a laboratory find a JAK2 fusion that routine testing misses?
Some JAK2 fusions are cryptic, meaning they are difficult to detect with standard tests. A laboratory with validated targeted RT-PCR, hybrid-panel, or RNA-sequencing assays may be able to identify the fusion and its partner.
When should I talk with a transplant physician?
Ask for a transplant consultation early enough to discuss whether stem cell transplantation could be appropriate for you. It is a potentially curative option for some patients, and your care team can determine the right timing based on your individual situation.
When might I need a cardio-oncology referral?
High eosinophil levels can affect the heart, so palpitations or shortness of breath should be reported to your care team. A cardio-oncologist can assess whether you need cardiac evaluation and specialized imaging.

Get notified when new evidence is published on Myeloid/lymphoid neoplasm associated with JAK2 rearrangement.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (13)
  1. 1

    Synoptic Diagnostics of Myeloproliferative Neoplasms: Morphology and Molecular Genetics.

    Nann D, Fend F

    Cancers 2021; (13(14)) doi:10.3390/cancers13143528.

    PMID: 34298741
  2. 2

    Role of allo-HCT in "nonclassical" MPNs and MDS/MPNs: recommendations from the PH&G Committee and the CMWP of the EBMT.

    Polverelli N, Hernández-Boluda JC, Onida F, et al.

    Blood 2025; (145(22)):2561-2573 doi:10.1182/blood.2024028000.

    PMID: 40106773
  3. 3

    How I diagnose and treat myeloid/lymphoid neoplasms with tyrosine kinase gene fusions.

    Reiter A, Metzgeroth G, Cross NCP

    Blood 2025; (145(16)):1758-1768 doi:10.1182/blood.2023022417.

    PMID: 39046810
  4. 4

    World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management.

    Shomali W, Gotlib J

    American journal of hematology 2024; (99(5)):946-968 doi:10.1002/ajh.27287.

    PMID: 38551368
  5. 5

    World Health Organization-defined eosinophilic disorders: 2022 update on diagnosis, risk stratification, and management.

    Shomali W, Gotlib J

    American journal of hematology 2022; (97(1)):129-148 doi:10.1002/ajh.26352.

    PMID: 34533850
  6. 6

    PCM1-JAK2 Fusion Tyrosine Kinase Gene-Related Neoplasia: A Systematic Review of the Clinical Literature.

    Kaplan HG, Jin R, Bifulco CB, et al.

    The oncologist 2022; (27(8)):e661-e670 doi:10.1093/oncolo/oyac072.

    PMID: 35472244
  7. 7

    Loeffler Syndrome in FIP1L1-PDGFRA-Positive Myeloid Neoplasm.

    Alcalá Ramírez Del Puerto M, Sánchez Sánchez C, Piñero Uribe I, et al.

    JACC. Case reports 2026; (31(5)):106296 doi:10.1016/j.jaccas.2025.106296.

    PMID: 41379052
  8. 8

    Two pediatric oncologic cases of hypereosinophilic syndrome and review of the literature.

    Voeller J, DeNapoli T, Griffin TC

    Cancer reports (Hoboken, N.J.) 2022; (5(11)):e1710 doi:10.1002/cnr2.1710.

    PMID: 36241191
  9. 9

    Next-generation sequencing RNA fusion panel for the diagnosis of haematological malignancies.

    Ngo TQ, Goh AFN, Dorwal P, et al.

    Pathology 2025; (57(3)):340-347 doi:10.1016/j.pathol.2024.09.009.

    PMID: 39672769
  10. 10

    Identification and Confirmation of Myeloid/Lymphoid Neoplasms with Fibroblast Growth Factor Receptor 1 Rearrangement and Characterization of Treatment Patterns and Outcomes in a Real-World Setting: A US Retrospective Chart Review.

    Parasuraman S, Saverno K, Zimmerman Savill KM, Colucci P

    Acta haematologica 2026; (149(3)):252-262 doi:10.1159/000546910.

    PMID: 40618748
  11. 11

    Myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions: reevaluation of the defining characteristics in a registry-based cohort.

    Metzgeroth G, Steiner L, Naumann N, et al.

    Leukemia 2023; (37(9)):1860-1867 doi:10.1038/s41375-023-01958-1.

    PMID: 37454239
  12. 12

    Integrated genomic analysis using chromosomal microarray, fluorescence in situ hybridization and mate pair analyses: Characterization of a cryptic t(9;22)(p24.1;q11.2)/BCR-JAK2 in myeloid/lymphoid neoplasm with eosinophilia.

    Snider JS, Znoyko I, Lindsey KG, et al.

    Cancer genetics 2020; (246-247()):44-47 doi:10.1016/j.cancergen.2020.08.004.

    PMID: 32827877
  13. 13

    Myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase fusion genes: A workshop report with focus on novel entities and a literature review including paediatric cases.

    Saft L, Kvasnicka HM, Boudova L, et al.

    Histopathology 2023; (83(6)):829-849 doi:10.1111/his.15021.

    PMID: 37551450

This page is for informational purposes only and does not constitute medical advice. Your hematologist-oncologist and specialist team should guide decisions about referrals, testing, and treatment for JAK2-rearranged MLN.